Current treatments

An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma. Nishihori T et al. Eur J Haematol. 2015 Jan 20. doi: 10.1111/ejh.12509. [Epub ahead of print]. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myelomanot eligible for or who deferred autologous stem cell transplantation.…

Details